ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.70
+0.09 (1.05%)
At close: Feb 20, 2026, 4:00 PM EST
8.70
0.00 (-0.02%)
After-hours: Feb 20, 2026, 7:59 PM EST
ImmunityBio Market Cap
ImmunityBio has a market cap or net worth of $8.57 billion as of February 20, 2026. Its market cap has increased by 267.90% in one year.
Market Cap
8.57B
Enterprise Value
9.17B
1-Year Change
267.90%
Ranking
Category
Stock Price
$8.70
Market Cap Chart
Since March 10, 2021, ImmunityBio's market cap has decreased from $14.82B to $8.57B, a decrease of -42.19%. That is a compound annual growth rate of -10.47%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 20, 2026 | 8.57B | 339.39% |
| Dec 31, 2025 | 1.95B | 4.33% |
| Dec 31, 2024 | 1.87B | -44.23% |
| Dec 29, 2023 | 3.35B | 61.49% |
| Dec 30, 2022 | 2.08B | -14.18% |
| Dec 31, 2021 | 2.42B | -83.68% |
| Mar 10, 2021 | 14.82B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ABIVAX Société Anonyme | 10.31B |
| Madrigal Pharmaceuticals | 9.98B |
| Praxis Precision Medicines | 9.34B |
| Axsome Therapeutics | 9.26B |
| Bio-Techne | 9.00B |
| Arrowhead Pharmaceuticals | 8.90B |
| Vaxcyte | 8.40B |
| Halozyme Therapeutics | 8.38B |